Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated NSCLC January 4, 2024
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1 December 19, 2023
Ph 3 INTerpath-002 Study of V940 (mRNA-4157) – KEYTRUDA combination for Adjuvant Treatment of Patients with Certain Types of Resected NSCLC December 19, 2023
Application submitted to the EMA for RYBREVANT + Chemo for the Treatment of Adult Patients with Advanced EGFR-Mutated NSCLC After Failure of Prior Therapy December 11, 2023
KEYLYNK-008 Trial of KEYTRUDA + LYNPARZA for Patients With Metastatic Squamous NSCLC to Stop for Futility December 11, 2023
Interim Data Presented from Two Ongoing Ph 2 Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation December 11, 2023
Findings from Ph 2 KeyVibe-002 Trial of Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with mNSCLC Announced December 11, 2023
Subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types December 4, 2023
FDA Approves Augtyro™ (repotrectinib) for the Treatment of Locally Advanced or Metastatic ROS1-Positive NSCLC December 4, 2023
Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs October 25, 2023
Tagrisso plus chemo granted Priority Review in the US for patients with EGFR-mutated advanced NSCLC October 25, 2023
FDA Approves KEYTRUDA for Treatment of Patients With Resectable (T≥4 cm or N+) NSCLC in Combination With Chemo as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After Surgery October 25, 2023
European Commission Approves KEYTRUDA as Adjuvant Treatment for Adults With NSCLC at High Risk of Recurrence Following Complete Resection & Platinum-Based Chemo October 25, 2023
Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of OS in Resectable Stage II, IIIA or IIIB NSCLC October 16, 2023
EXKIVITY® (mobocertinib) to be voluntary withdrawn from the U.S. for adult patients with EGFR Exon20 insertion+ mNSCLC whose disease has progressed on or after platinum-based chemotherapy October 11, 2023
Nektar Therapeutics and Cellular Biomedicine Group to Evaluate NKTR-255 + C-TIL051 in Advanced NSCLC October 3, 2023
Ph 3 MARIPOSA Study Meets Primary Endpoint of PFS for RYBREVANT (amivantamab-vmjw) + Lazertinib vs Osimertinib in EGFR-Mutated NSCLC October 3, 2023
FDA grants Fast Track Designation to MYTX-011 for Patients with NSCLC with cMET Overexpression October 3, 2023
FAILED TRIALS: Ph 3 trials, LEAP-006 and LEAP-008, of KEYTRUDA + LENVIMA in patients with certain types of mNSCLC did not meet primary endpoints of OS & PFS September 26, 2023
Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves EFS in Patients with Resectable NSCLC September 26, 2023
Ph 2 EVOKE-02 Study Of Trodelvy + KEYTRUDA Demonstrates Promising Clinical Activity In 1L mNSCLC September 19, 2023
